FDA Says It Is Investigating Potential Link Between Vytorin and Risk of Cancer (MRK, SGP)
More News related to MRK
- New Study Data: JANUVIA(TM) (sitagliptin) Significantly Reduced Blood Sugar Levels and Was Not Associated with Hypoglycemia in Elderly Patients with Type 2 Diabetes
- Idera Pharmaceuticals (IDRA) and Merck (MRK) Extend Research Collaboration for 1-Yr
- Merck Announces Voluntary Delisting from Philadelphia Stock Exchange
- GARDASIL(R), Merck's Cervical Cancer Vaccine, Demonstrated Efficacy in Preventing HPV-Related Disease in Males in Phase III Study
- Merck Reaffirms Cardiovascular Research Commitment
More News related to SGP
- Notable Analyst Rating Changes 11/14: CLX, LDK, ALO, URBN Upgraded; GSK, EMR, LHO, UDR Downgraded
- Banc of America Starts Schering-Plough (SGP) and Pfizer (PFE) at Buy
- Relational Investors Raises Stakes In Yahoo! (YHOO) and Sun Microsystems (JAVA), Shows New Stake In Schering-Plough (SGP)
- Redpoint Bio Signs Pharmaceutical Research Agreement with Schering Corporation
- Schering-Plough to Webcast R&D Update Meeting
More News related to Corporate News
- Citi Initiates Coverage on US Soft Drink Makers
- William Blair Initiates Coverage on Data Networking Stocks
- Caris Starts Coverage on Ariba (ARBA), Concur (CNQR), salesforce.com (CRM), Taleo (TLEO)
- Oppenheimer Initiates Coverage on ViroPharma (VPHM)
- Oppenheimer Initiates Coverage on Cadence Pharmaceuticals (CADX) with an Outperform
The U.S. FDA has posted information on its website that it is reviewing potential cancer risks related to cholesterol drugs. The agency cites a report of a possible link in study of Merck (NYSE: MRK) and Schering-Plough's (NYSE: SGP) Vytorin.
Merck & Co., Inc. provides various products for human and animal health in the United States and internationally.
Schering-Plough Corporation discovers, develops, manufactures, and sells pharmaceuticals worldwide.
Related Categories
Corporate NewsFDA
Stocks Mentioned
+0.84Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
